編號
R3-004
徵稿主題
Clinical Trial / Chemotherapy / Targeted Therapy / Immunotherapy / Cell Therapy
題目
台灣多中心真實世界研究：HR+/HER2− 轉移性乳癌CDK4/6 抑制劑治療後第一線口服節拍式合併化療（VEX-based）之療效與安全性
作者群
羅景州1,
林敬翰2,3,
林金瑤4,
魏敬庭5,6,
高理鈞1,7
服務單位
1 Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807377, Taiwan
2 Breast Surgical Oncology Department, Changhua Christian Hospital, Changhua 500209, Taiwan
3 Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua 500209, Taiwan
4 Breast Medical Center, Division of General Surgery, Department of Surgery, Taichung Tzu Chi Hospital, Taichung 427003, Taiwan
5 The School of Chinese Medicine for Post Baccalaureate, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan
6 Division of General Surgery, Department of Surgery, E-Da Hospital, I-Shou University, Kaohsiung 82445, Taiwan
7 Doctoral Program of Clinical and Experimental Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung 804201, Taiwan
